SCHEMBL2310751

SCHEMBL2310751

COC(=O)c1cc(OCc2ccccc2)ncc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ MEN1 O00255 1/20 0.44
▸ PABPC1 P11940 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CNR1 P21554 1/20 0.43
▸ HCRTR1 O43613 2/20 0.43
▸ HCRTR2 O43614 2/20 0.43
▸ LRRK2 Q5S007 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ CXCR2 P25025 1/20 0.42
▸ THRA P10827 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ FOLH1 Q04609 1/20 0.42
▸ GABRG2 P18507 1/20 0.41
▸ GABRB3 P28472 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ SMPD1 P17405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22715422 0.86 FOLH1 (0.52) MEN1KMT2ALRRK2L3MBTL1PKM
SCHEMBL29472138 0.86 FOLH1 (0.52) MEN1KMT2ALRRK2L3MBTL1PKM
SCHEMBL4283870 0.84 LMNA (0.49) LMNAHPGDMEN1PABPC1KMT2A
SCHEMBL29472101 0.84 GABRG2 (0.46) CNR1LRRK2L3MBTL1CXCR2THRA
SCHEMBL22715861 0.84 GABRG2 (0.46) CNR1LRRK2L3MBTL1CXCR2THRA
SCHEMBL13424079 0.82 LMNA (0.47) LMNAHPGDMEN1PABPC1KMT2A
SCHEMBL2312774 0.82 FFAR1 (0.46) LMNAHPGDMEN1PABPC1KMT2A
SCHEMBL20607719 0.81 LMNA (0.48) LMNAHPGDMEN1PABPC1KMT2A
SCHEMBL24770289 0.80 HCRTR1 (0.42) LMNAMEN1KMT2AHCRTR1HCRTR2
SCHEMBL30017651 0.80 HCRTR1 (0.42) LMNAMEN1KMT2AHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897877-B2 Inhibitor compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-02-13 — — US disclosed
US-20220402912-A1 INHIBITOR COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2022-12-22 — — US disclosed
US-20220402912-A1 INHIBITOR COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2022-12-22 — — US disclosed
US-11046688-B2 Inhibitor compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-06-29 — — US disclosed
US-11046688-B2 Inhibitor compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-06-29 — — US disclosed
US-20200165241-A1 INHIBITOR COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2020-05-28 — — US disclosed
US-20200165241-A1 INHIBITOR COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2020-05-28 — — US disclosed
US-10479788-B2 Compounds that inhibit MPS1 kinase CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-11-19 — — US disclosed
US-10479788-B2 Compounds that inhibit MPS1 kinase CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-11-19 — — US disclosed
EP-3293183-B1 INHIBITOR COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2019-07-24 — — EP disclosed
WO-2014037750-A1 INHIBITOR COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-03-13 — — WO disclosed
WO-2014037750-A1 INHIBITOR COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-03-13 — — WO disclosed
EP-2358656-B1 SPIROCYCLIC GPR40 MODULATORS AMGEN INC (US) 2014-01-01 — — EP disclosed
EP-2358656-B1 SPIROCYCLIC GPR40 MODULATORS AMGEN INC (US) 2014-01-01 — — EP disclosed
EP-2358656-A2 SPIROCYCLIC GPR40 MODULATORS Amgen, Inc (US) 2011-08-24 — — EP disclosed
US-20110190330-A1 SPIROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2011-08-04 — — US disclosed
US-20110190330-A1 SPIROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2011-08-04 — — US disclosed
US-20110190330-A1 SPIROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2011-08-04 — — US disclosed
WO-2010045258-A2 SPIROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2010-04-22 — — WO disclosed
WO-2010045258-A2 SPIROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479788-B2 Compounds that inhibit MPS1 kinase BUB1B, BUB1, CDK1 LMNA 1312/4885HPGD 4473/4885MEN1 601/4885
US-20220402912-A1 INHIBITOR COMPOUNDS BUB1B, BUB1, CDK1 LMNA 1306/4885HPGD 4376/4885MEN1 457/4885
US-11046688-B2 Inhibitor compounds BUB1B, BUB1, CDK1 LMNA 1306/4885HPGD 4376/4885MEN1 457/4885
US-20110190330-A1 SPIROCYCLIC GPR40 MODULATORS GPR119, GPR55, GPR65 LMNA 2955/4885HPGD 912/4885MEN1 2435/4885
US-11897877-B2 Inhibitor compounds BUB1B, BUB1, CDK1 LMNA 1306/4885HPGD 4376/4885MEN1 457/4885
US-20200165241-A1 INHIBITOR COMPOUNDS BUB1B, BUB1, CDK1 LMNA 1306/4885HPGD 4376/4885MEN1 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback